Similar articles

• Initial management of deep venous thrombosis in the outpatient setting.

  Groce JB. Groce JB. Am J Health Syst Pharm. 2008 May 1;65(9):866-74. doi: 10.2146/ajhp070408. Am J Health Syst Pharm. 2008. PMID: 18436734 No abstract available.
• Fondaparinux for the treatment of superficial-vein thrombosis in the legs.

  Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, Matyas L, Middeldorp S, Sokurenko G, Leizorovicz A; CALISTO Study Group. Decousus H, et al. N Engl J Med. 2010 Sep 23;363(13):1222-32. doi: 10.1056/NEJMoa0912072. N Engl J Med. 2010. PMID: 20860504 Clinical Trial.
• Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis.

  Blondon M, Righini M, Bounameaux H, Veenstra DL. Blondon M, et al. Chest. 2012 Feb;141(2):321-329. doi: 10.1378/chest.11-0625. Epub 2011 Jul 14. Chest. 2012. PMID: 21757569
• Treatment of venous thromboembolism: duration and new options.

  Huisman MV. Huisman MV. Hematol J. 2004;5 Suppl 3:S24-8. doi: 10.1038/sj.thj.6200417. Hematol J. 2004. PMID: 15190273 Review. No abstract available.
• The treatment of deep venous thrombosis, including the newer agents.

  Rectenwald JE, Wakefield TW. Rectenwald JE, et al. Dis Mon. 2005 Feb-Mar;51(2-3):104-11. doi: 10.1016/j.disamonth.2005.03.004. Dis Mon. 2005. PMID: 15900261 Review. No abstract available.